Cherry Ventures’ Post

Understanding and treating brain disorders remains one of medicine's greatest challenges. Early diagnosis is rare, treatments struggle to reach their targets, and monitoring disease progression is nearly impossible with current tools. Robeauté is pioneering a new era in brain medicine. Their microrobots - smaller than a grain of rice - can navigate curved paths through the brain, enabling surgeons to diagnose early, deliver treatments precisely, and monitor effectiveness in real-time. At Cherry, we back European founders solving global challenges. Robeauté's technology led by Bertrand Duplat & Joana Cartocci could transform how we diagnose and treat neurological disorders worldwide. That's why it was a no-brainer to co-lead their $28M round alongside @Plural and @Kindred Ventures. What's next: • Moving toward human trials in 2026 • Setting up US operations for FDA approval • Building out their world-class team combining robotics and medical expertise Learn more about Robeauté, their microbots, and investment here: https://lnkd.in/epqdmGqD Filip Felician Dames Christian Meermann Sophia Bendz Dinika Mahtani Jasper Masemann Alexander Langholz-Baikousis

To view or add a comment, sign in

Explore topics